PNIBLOG

Clinical Trials Round-Up at PNI

We have added a new clinical trial to our roster of brain tumor trials at the Pacific Neuroscience Research Center at PNI.

NEW CLINICAL TRIAL

Orbus Therapeutics (NCT02796261): A Randomized Phase 3 Open-Label Study To Evaluate the Efficacy and Safety of Eflornithine With Lomustine Compared to Lomustine Alone in Patients With Anaplastic Astrocytoma That Progress/Recur After Irradiation and Adjuvant Temozolomide Chemotherapy. Download pdf flyer

 

ACTIVELY RECRUITING TRIALS

Glioblastoma 

AbbVie / RTOG (NCT02573324): A Study of ABT-414 in Subjects With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification. Download pdf flyer

Boehringer Ingelheim (NCT02423525): A Phase I Dose Escalation and CNS Pharmacokinetic Study of the ErbB Family Inhibitor Afatinib in Patients with Recurrent or Progressive Brain Cancer. Download pdf flyer

Inspyr Therapeutics (NCT02876003): Efficacy, Safety and CNS Exposure of G-202 in Patients with PSMA-Positive Recurrent or Progressive Glioblastoma. Download pdf flyer

ImmunoCellular (NCT02546102): A Phase III randomized double-blind, controlled study of ICT-107 with maintenance temozolomide (TMZ) in newly diagnosed glioblastoma following resection and concomitant TMZ chemoradiotherapy. Download pdf flyer

Nativis (NCT02296580): A Feasibility Study of the Nativis Voyager System in Patients With Recurrent Glioblastoma Multiforme (GBM). Download pdf flyer

 

Brain Metastases

Boehringer Ingelheim (NCT02423525): A Phase I Dose Escalation and CNS Pharmacokinetic Study of the ErbB Family Inhibitor Afatinib in Patients with Recurrent or Progressive Brain Cancer. Download pdf flyer

Eli Lilly and Company (NCT02308020): A Phase 2 Study of Abemaciclib in Patients With Brain Metastases Secondary to Hormone Receptor Positive Breast Cancer, Non-small Cell Lung Cancer, or Melanoma. Download pdf flyer 

EpiCentRX (NCT02215512): Dose-Escalation Study of RRx-001 in Combination With Whole Brain Radiation in Subjects With Brain Metastases (BRAINSTORM). Download pdf flyer

Kadmon (NCT02616393): Study of Tesevatinib in Subjects With Non-Small Cell Lung Cancer, EGFR Activating Mutation, Prior Treatment With a Tyrosine Kinase Inhibitor, and Brain Metastases or Leptomeningeal Metastases. Download pdf flyer

If you or your physician are considering entering into a study, please review full details of each of our clinical trials by clicking on the pdf flyer downloads.

Investigators:
Achal S. Achrol, MD
Garni Barkhoudarian, MD
Daniel Kelly, MD
Santosh Kesari MD, PhD, FANA, FAAN
Steven O’Day, MD

Clinical Trial Team:
Najee Boucher, CRA  |  310-582-7460
Jaya M. Gill, RN, BSN  |  310-582-7437
Annie Heng, RN, BSN   |  310-582-7457
Marlon Garzo Saria, MSN, RN, AOCNS, FAAN  |  310-582-7340

For more information, please contact the Neuro-Oncology Clinical Trial Team at:
e-mail: neuro.oncology@jwci.org
phone: 310-829-8265